随机免疫疗法研究中响应率与生存益处之间的关系
1Edinburgh Medical School, Biomedical Sciences, The University of Edinburgh, Edinburgh EH8 9YL, UK.
Cancers
|February 13, 2025
概括
目标反应率 (ORR) 在免疫瘤学试验中适度预测无进展生存 (PFS),但预测整体生存 (OS) 却很弱,特别是在组合疗法中. ORR是长期结果的有限替代品.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 免疫疗法研究 免疫疗法研究
背景情况:
- 评估癌症治疗疗效需要了解目标响应率 (ORR) 与生存结果 (如无进展生存 (PFS) 和整体生存 (OS)) 之间的联系.
- 免疫瘤学 (IO) 疗法,包括免疫检查点抑制剂 (例如,抗PD-L1,CTLA-4) 和组合疗法,正在改变癌症护理.
研究的目的:
- 在免疫瘤治疗方案的临床试验中评估ORR,PFS和OS之间的关系.
- 确定ORR作为IO治疗试验中生存结果的替代终点的可靠性.
主要方法:
- 来自FDA提交的55项临床试验的数据分析,涉及各种免疫治疗方案 (IO,anti-PD-(L) 1,CTLA-4和组合).
- 包括标准要求试验报告ORR,PFS和OS.
- 进行了相关性分析,以评估ORR和生存指标之间的关系.
主要成果:
- 在大多数IO疗法中观察到ORR和PFS之间的中等相关性,这表明ORR对预测短期疾病控制的实用性.
- ORR和OS之间的相关性较弱,特别是在组合疗法试验中,这表明ORR对长期存活的预测价值有限.
- 与后续线相比,ORR对PFS的预测能力在一线治疗中更强.
结论:
- 目标反应率 (ORR) 在免疫瘤学 (IO) 试验中作为无进展生存率 (PFS) 的有用替代品,但对预测整体生存率 (OS) 的实用性有限.
- 在不同治疗线和组合策略中,ORR对生存结果的预测准确性差异很大.
- 需要进一步的研究来开发更好的免疫疗法代用终点,以提高临床试验设计和患者的结果.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
127
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
127
Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
Actuarial Approach
54
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
54
Cancer Survival Analysis
321
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
321
Kaplan-Meier Approach
80
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
80
Assumptions of Survival Analysis
84
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
84


